CRO CMO Small to mid-size pharma clients seeking full discovery and development support in the USA can leverage Kinentia’s in-house preclinical and clinical capabilities as a one-stop CRO/CMO solution, reducing vendor coordination and timelines.

Chemo-informatics edge Kinentia combines medicinal chemistry, process R&D, CMC dossier support with platform chemo-informatics, presenting a cross-disciplinary value proposition to accelerate drug discovery programs and mitigate development risk for potential clients.

Catalog potential Through KCS-Online, there is an accessible catalog of novel chemical intermediates and drug-like building blocks, offering pathways for customers to source unique materials that can de-risk early development and support outsourcing engagements.

US-based advantage All discovery and development activities are conducted in the USA, which can appeal to clients prioritizing domestic regulatory alignment, faster communication, and compliance with U.S. pharmacopeia standards.

Strategic partnerships With consulting services and a broad tech stack, Kinentia is positioned to partner on end-to-end programs, offering ongoing advisory, data-driven chemistry optimization, and potential repeat engagement opportunities for ongoing development programs.